#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Vztah mezi polymorfizmy genů nukleotidové excizní reparace a náchylností ke kožnímu melanomu


Autoři: A. Hashemzehi 1;  M. Ghadyani 2;  F. Asadian 3;  S. A. Dastgheib 4;  S. Kargar 5;  H. Neamatzadeh 6,7;  E. Akbarian 8;  A. Emarati 8
Působiště autorů: Department of Pharmacology, Faculty of Pharmacology, Tehran University of Medical Sciences, Tehran, Iran 1;  Department of Advanced Medical Sciences and Technologies, Islamic Azad University, Science and Research Branch, Tehran, Iran 2;  Department of Medical Laboratory Sciences, School of Paramedical Science, Shiraz University of Medical Sciences, Shiraz, Iran 3;  Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran 4;  Department of General Surgery, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 5;  Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 6;  Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 7;  Children Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 8
Vyšlo v časopise: Klin Onkol 2021; 34(5): 350-355
Kategorie: Přehledy
doi: https://doi.org/10.48095/ccko2021350

Souhrn

Východiska: Účinky jednonukleotidových polymorfizmů (single nucleotide polymorphisms –⁠ SNPs) genů nukleotidové excizní reparace (nucleotide excision repair –⁠ NER) na náchylnost ke kožnímu melanomu (cutaneous melanoma –⁠ CM) jsou předmětem velkého zájmu. V současné době je v několika epidemiologických studiích hodnoceno, zda polymorfizmy XPC, XPD, XPG a XPF souvisí s CM. Výsledky těchto studií jsou ale kontroverzní nebo nevedou k jednoznačnému závěru. Proto jsme provedli studii s cílem zhodnotit vztah mezi sedmi často zkoumanými polymorfizmy dráhy NER a rizikem CM. Metody: Do studie bylo zařazeno celkem 150 patients s dia­gnózou CM a 150 zdravých kontrol. Sedm SNPs dráhy NER vč. XPC (Lys939Gln a Ala499Val), XPD (Lys157Gln, Asp272Asn a Arg751Arg), XPG (Asp1104His) a XPF (Arg415Gln) bylo analyzováno stanovením polymorfizmu délky štěpných fragmentů pomocí polymerázové řetězové reakce. Výsledky: Mezi polymorfizmy XPC Lys939Gln, Ala499Val, XPD Asp272Asn, Arg751Arg, Arg751Arg, XPF Arg415Gln a XPG Asp1104His a zvýšeným rizikem CM nebyl zjištěn významný vztah. Závěry: Tato studie odhalila, že polymorfizmy XPC, XPD, XPG a XPF nebyly pro náchylnost k CM rizikovým faktorem. Pro další hodnocení a validaci našich výsledků je třeba více studií s dobrým designem a vyšším počtem subjektů v různých populacích. Přesnější důkazy a další objasnění vlastního mechanizmu CM přinesou v budoucnosti studie, které budou brát v úvahu interakce mezi geny jako takovými a mezi geny a prostředím.

Klíčová slova:

jednonukleotidový polymorfizmus – kožní melanom – nukleotidová excizní reparace – vztah


Zdroje

1. Ghaemmaghami F, Zarchi MK, Gilani MM et al. Uterine sarcoma: clinicopathological characteristics, treatment and outcome in Iran. Asian Pac J Cancer Prev 2008; 9 (3): 421–426.

2. Behtash N, Karimi Zarchi M, Deldar M. Preoperative prognostic factors and effects of adjuvant therapy on outcomes of early stage cervical cancer in Iran. Asian Pac J Cancer Prev 2009; 10 (4): 613–618.

3. Karimi Zarchi M, Akhavan A, Gholami H et al. Evaluation of cervical cancer risk-factors in women referred to Yazd-Iran hospitals from 2002 to 2009. Asian Pac J Cancer Prev 2010; 11 (2): 537–538.

4. Ghaemmaghami F, Zarchi MK, Mousavi A. Surgical management of primary vulvar lymphangioma circumscriptum and postradiation: case series and review of literature. J Minim Invasive Gynecol 2008; 15 (2): 205–208. doi: 10.1016/j.jmig.2007.09.005.

5. Binesh F, Zarchi MK, Vahedian H et al. Primary malignant lymphoma of the uterine cervix. BMJ Case Rep 2012; 2012: bcr2012006675. doi: 10.1136/bcr-2012-006675.

6. Niktabar SM, Latifi SM, Moghimi M et al. Association of vitamin D receptor gene polymorphisms with risk of cutaneous melanoma. A meta-analysis based on 40 case-control studies. Dermatol Rev/Przegl Dermatol 2019; 106 : 268–279. doi: 10.5114/dr.2019.86909.

7. Iglesias-Pena N, Paradela S, Tejera-Vaquerizo A et al. Cutaneous melanoma in the elderly: review of a growing problem. Actas Dermosifiliogr 2019; 110 (6): 434–447. doi: 10.1016/j.ad.2018.11.009.

8. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (5): E359–386. doi: 10.1002/ijc.29210.

9. Cormier JN, Xing Y, Ding M et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med 2006; 166 (17): 1907–1914. doi: 10.1001/archinte.166.17.1907.

10. Melanoma stats, facts, and figures n.d. [online]. Available from: http: //www.optisigma.pt/editor/wp-content/uploads/2016/11/Melanoma-Stats-Facts-and-Figures-AIM-at-Melanoma.pdf.

11. Leonardi GC, Falzone L, Salemi R et al. Cutaneous melanoma: from pathogenesis to therapy (review). Int J Oncol 2018; 52 (4): 1071–1080. doi: 10.3892/ijo.2018.4287.

12. Yu J, Luo X, Huang H et al. Clinical characteristics of malignant melanoma in southwest China: a single-center series of 82 consecutive cases and a meta-analysis of 958 reported cases. PLoS One 2016; 11 (11): e0165591. doi: 10.1371/journal.pone.0165591.

13. Read J, Wadt KAW, Hayward NK. Melanoma genetics. J Med Genet 2016; 53 (1): 1–14. doi: 10.1136/jmedgenet -⁠ 2015-103150.

14. Leibeling D, Laspe P, Emmert S. Nucleotide excision repair and cancer. J Mol Histol 2006; 37 (5–7): 225–238. doi: 10.1007/s10735-006-9041-x.

15. Paszkowska-Szczur K, Scott RJ, Serrano-Fernandez P et al. Xeroderma pigmentosum genes and melanoma risk. Int J Cancer 2013; 133 (5): 1094–1100. doi: 10.1002/ijc.28123.

16. Jackson SP, Bartek J. The DNA-damage response in human bio­logy and disease. Nature 2009; 461 (7267): 1071–1078. doi: 10.1038/nature08467.

17. Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutag 2017; 58 (5): 235–263. doi: 10.1002/em.22087.

18. Petruseva IO, Evdokimov AN, Lavrik OI. Molecular mechanism of global genome nucleotide excision repair. Acta Naturae 2014; 6 (1): 23–34. doi: 10.32607/20758251-2014-6-1-23-34.

19. Han C, Huang X, Hua R et al. The association between XPG polymorphisms and cancer susceptibility: evidence from observational studies. Medicine 2017; 96 (32): e7467. doi: 10.1097/MD.0000000000007467.

20. Ge J, Liu H, Qian D et al. Genetic variants of genes in the NER pathway associated with risk of breast cancer: a large-scale analysis of 14 published GWAS datasets in the DRIVE study. Int J Cancer 2019; 145 (5): 1270–1279. doi: 10.1002/ijc.32371.

21. Blankenburg S, König IR, Moessner R et al. Assessment of 3 xeroderma pigmentosum group C gene poly­morphisms and risk of cutaneous melanoma: a case–control study. Carcinogenesis 2005; 26 (6): 1085–1090. doi: 10.1093/carcin/bgi055.

22. Wu K-G, He X-F, Li Y-H et al. Association between the XPD/ERCC2 Lys751Gln polymorphism and risk of cancer: evidence from 224 case-control studies. Tumour Biol 2014; 35 (11): 11243–11259. doi: 10.1007/s13277-014-2379-x.

23. Li C, Hu Z, Liu Z et al. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev 2006; 15 (12): 2526–2532. doi. 10.1158/1055-9965.EPI-06-0672.

24. ElMahgoub IR, Gouda HM, Samra MA et al. Polymorphisms of xeroderma pigmentosum genes (XPC, XPD, and XPG) and susceptibility to acute leukemia among a sample of Egyptian patients. J Hematopathol 2017; 10 (6): 3–7. doi: 10.1007/s12308-017-0290-2.

25. López-Cima MF, González-Arriaga P, García-Castro L et al. Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of Northern Spain. BMC Cancer 2007; 7 : 162. doi: 10.1186/1471-2407-7-162.

26. Yang ZH, Liang WB, Jia J et al. The xeroderma pigmentosum group C gene polymorphisms and genetic susceptibility of nasopharyngeal carcinoma. Acta Oncol 2008; 47 (3): 379–384. doi: 10.1080/02841860701558815.

27. Yousaf S, Khan MI, Micheal S et al. XRCC1 and XPD DNA repair gene polymorphisms: a potential risk factor for glaucoma in the Pakistani population. Mol Vis 2011; 17 : 1153–1163.

28. Zhou C, Xie L-P, Lin Y-W et al. Susceptibility of XPD and hOGG1 genetic variants to prostate cancer. Biomed Rep 2013; 1 (4): 679–683. doi: 10.3892/br.2013.123.

29. Zhu S, Wang A, Xia Z. Polymorphisms of DNA repair gene XPD and DNA damage of workers exposed to vinylchloride monomer. Int J Hyg Environ Health 2005; 208 (5): 383–390. doi: 10.1016/j.ijheh.2005.05.002.

30. Povey JE, Darakhshan F, Robertson K et al. DNA repair gene polymorphisms and genetic predisposition to cutaneous melanoma. Carcinogenesis 2007; 28 (5): 1087–1093. doi: 10.1093/carcin/bgl257.

31. Torres SM, Luo L, Lilyquist J et al. DNA repair variants, indoor tanning, and risk of melanoma. Pigment Cell Melanoma Res 2013; 26 (5): 677–684. doi: 10.1111/pcmr.12 117.

32. Jiang W, Zhang H, Chen QW et al. A meta-analysis of XPC Lys939Gln polymorphism and melanoma susceptibility. J Eur Acad Dermatol Venereol 2016; 30 (8): 1327–1331. doi: 10.1111/jdv.13477.

33. Hua RX, Zhu ZJ, Shen GP et al. Polymorphisms in the XPC gene and gastric cancer susceptibility in a Southern Chinese population. OncoTargets Ther 2016; 9 : 5513–5519. doi: 10.2147/OTT.S113055.

34. Zhou L, Lu Y, Yang G et al. Quantitative assessment of the association between XPC Lys939Gln polymorphism and cutaneous melanoma risk. Tumor Biol 2014; 35 (2): 1427–1432. doi: 10.1007/s13277-013-1196-y.

35. Zhao F, Shang Y, Zeng C et al. Association of single nucleotide polymorphisms of DNA repair genes in NER pathway and susceptibility to pancreatic cancer. Int J Clin Exp Pathol 2015; 8 (9): 11579–11586.

36. Winsey SL, Haldar NA, Marsh HP et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 2000; 60 (20): 5612–5616.

37. Dębniak T, Scott RJ, Huzarski T et al. XPD common variants and their association with melanoma and breast cancer risk. Breast Cancer Res Treat 2006; 98 (2): 209–215. doi: 10.1007/s10549-005-9151-2.

38. Sun Y, Zhang H, Ying H et al. A meta-analysis of XPD/ERCC2 Lys751Gln polymorphism and melanoma susceptibility. Int J Clin Exp Med 2015; 8 (8): 13874–13878.

39. Liu J, Song J, Wang M-Y et al. Association of EGF rs4444903 and XPD rs13181 polymorphisms with cutaneous melanoma in Caucasians. Med Chem 2015; 11 (6): 551–559. doi: 10.2174/1573406410666141224115516.

40. Zhu H-L, Bao J-M, Lin P-X et al. XPD Lys751Gln and Asp312Asn polymorphisms and susceptibility to skin cancer: a meta-analysis of 17 case-control studies. Asian Pac J Cancer Prev 2014; 15 (16): 6619–6625. doi: 10.7314/apjcp.2014.15.16.6619.

41. Xu Y, Jiao G, Wei L et al. Current evidences on the XPG Asp1104His polymorphism and melanoma susceptibility: a meta-analysis based on case-control studies. Mol Genet Genomics 2015; 290 (1): 273–279. doi: 10.1007/s00438-014-0917-2.

42. Manandhar M, Boulware KS, Wood RD. The ERCC1 and ERCC4 (XPF) genes and gene products. Gene 2015; 569 (2): 153–161. doi: 10.1016/j.gene.2015.06.026.

43. Emmert S. The human XPG gene: gene architecture, alternative splicing and single nucleotide polymorphisms. Nucleic Acids Res 2001; 29 (7): 1443–1452. doi: 10.1093/nar/29.7.1443.

44. Li C, Hu Z, Liu Z et al. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev 2006; 15 (12): 2526–2532. doi: 10.1158/1055-9965.EPI-06-0672.

45. He X-F, Liu L-R, Wei W et al. Association between the XPG Asp1104His and XPF Arg415Gln polymorphisms and risk of cancer: a meta-analysis. PLoS One 2014; 9 (5): e88490. doi: 10.1371/journal.pone.0088490.

46. Wang M, Li Q, Gu C et al. Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations. Oncotarget 2017; 8 (15): 24362–24371. doi: 10.18632/oncotarget.13848.

47. Schärer OD. ERCC1/XPF endonuclease-positioned to cut. EMBO J 2017; 36 (14): 1993–1995. doi: 10.15252/embj.201797489.

48. Oliveira C, Rinck-Junior JA, Lourenço GJ et al. Assessment of the XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro) and GSTP1 (Ile105Val) polymorphisms in the risk of cutaneous melanoma. J Cancer Res Clin Oncol 2013; 139 (7): 1199–1206. doi: 10.1007/s00432-013-1430-4.

49. Gomez GVB, de Oliveira C, Rinck-Junior JA et al. XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro), and GSTP1 (Ile105Val) polymorphisms in prognosis of cutaneous melanoma. Tumour Biol 2016; 37 (3): 3163–3171. doi: 10.1007/s13277-015-4123-6.

Štítky
Dětská onkologie Chirurgie všeobecná Onkologie

Článek vyšel v časopise

Klinická onkologie

Číslo 5

2021 Číslo 5
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

BONE ACADEMY 2025
nový kurz
Autoři: prof. MUDr. Pavel Horák, CSc., doc. MUDr. Ludmila Brunerová, Ph.D, doc. MUDr. Václav Vyskočil, Ph.D., prim. MUDr. Richard Pikner, Ph.D., MUDr. Olga Růžičková, MUDr. Jan Rosa, prof. MUDr. Vladimír Palička, CSc., Dr.h.c.

Cesta pacienta nejen s SMA do nervosvalového centra
Autoři: MUDr. Jana Junkerová, MUDr. Lenka Juříková

Eozinofilní zánět a remodelace
Autoři: MUDr. Lucie Heribanová

Hypertrofická kardiomyopatie: Moderní přístupy v diagnostice a léčbě
Autoři: doc. MUDr. David Zemánek, Ph.D., MUDr. Anna Chaloupka, Ph.D.

Vliv funkčního chrupu na paměť a učení
Autoři: doc. MUDr. Hana Hubálková, Ph.D.

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#